Trial Profile
A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of CriPec Docetaxel in Patients With Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Acronyms NAPOLY
- Sponsors Cristal Therapeutics
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 17 May 2019 Results published in the Media Release
- 17 May 2019 According to a Cristal Therapeutics media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting. Florence Atrafi is one of the clinical investigators.